Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

BMC Veterinary Research

Volumn 9, Issue , 2013, Pages

  Maniscalco, Lorella ^a   Millán, Yolanda ^b   Iussich, Selina ^a   Denina, Mauro ^a   Sánchez Céspedes, Raquel ^b   Gattino, Francesca ^a   Biolatti, Bartolomeo ^a   Sasaki, Nobuo ^c   Nakagawa, Takayuki ^c   Di Renzo, Maria Flavia ^d   de las Mulas, Juana Martín ^b   De Maria, Raffaella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FELIDAE; MAMMALIA;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL; CAT; CAT DISEASE; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; UDDER; VETERINARY; WESTERN BLOTTING; ANIMAL DISEASE; ARTICLE;

ANIMALS; BLOTTING, WESTERN; CAT DISEASES; CATS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TOR SERINE-THREONINE KINASES;

EID: 84876127232     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-9-80     Document Type: Article

References (44)

1. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012, 23(9):2223-2234. 10.1093/annonc/mds067, 22517820.
2. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010, 4(3):209-229. 10.1016/j.molonc.2010.04.006, 20537966.
3. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast 2012, 21(2):178-182. 10.1016/j.breast.2011.09.008, 21963359.
4. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430. 10.1038/nature04869, 16724053.
5. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2(4):296-313. 10.1038/nrd1066, 12669029.
6. Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344(Pt 2):427-431. 1220660, 10567225.
7. Margariti N, Fox SB, Bottini A, Generali D. " Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. Breast Cancer Res Treat 2011, 128(3):599-606. 10.1007/s10549-010-0986-9, 20945086.
8. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000, 103(2):253-262. 10.1016/S0092-8674(00)00117-3, 11057898.
9. Villarreal-Garza C, Cortes J, Andre F, Verma S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 2012, 23(10):2526-2535. 10.1093/annonc/mds075, 22553196.
10. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13(19):5883-5888. 10.1158/1078-0432.CCR-06-2837, 17908983.
11. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009, 15(17):5404-5413. 10.1158/1078-0432.CCR-09-0365, 2743856, 19690197.
12. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010, 28(20):3366-3379. 10.1200/JCO.2009.25.4011, 20530283.
13. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004, 6(5):219-224. 10.1186/bcr927, 549184, 15318929.
14. An J, Jeong H, Lee Y, Woo SU, Seo JH, Kim A. Phosphorylated Akt and Phosphorylated mTOR Expression in Breast Invasive Carcinomas: Analysis of 530 Cases. Journal of Breast Cancer 2010, 13:4.
15. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011, 121(4):1231-1241. 10.1172/JCI44145, 3069769, 21490404.
16. Misdorp W, Weijer K. Animal model of human disease: breast cancer. Am J Pathol 1980, 98(2):573-576. 1903412, 6986788.
17. Martín De Las Mulas J, Millán Y, Bautista M, Pérez J, Carrasco L. Oestrogen and progesterone receptors in feline fibroadenomatous change: an immunohistochemical study. Res Vet Sci 2000, 68(1):15-21. 10.1053/rvsc.1999.0327, 10684753.
18. Mulas JM D, van Niel M, Millán Y, Blankenstein MA, Van Mil F, Misdorp W. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol 2000, 18(1):111-125. 10.1016/S0739-7240(99)00067-3, 10701768.
19. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005, 65(3):907-912.
20. Millanta F, Calandrella M, Vannozzi I, Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec 2006, 158(24):821-824. 10.1136/vr.158.24.821, 16782855.
21. Martín De Las Mulas JM, Van Niel M, Millan Y, Ordas J, Blankenstein MA, Van Mil F, Misdorp W. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci 2002, 72(2):153-161. 10.1053/rvsc.2001.0542, 12027597.
22. Maniscalco L, Iussich S, de Las Mulas JM, Millán Y, Biolatti B, Sasaki N, Nakagawa T, De Maria R. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J 2012, 191(1):65-71. 10.1016/j.tvjl.2010.12.016, 21282070.
23. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005, 42(1):30-34. 10.1354/vp.42-1-30, 15657269.
24. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1-2):4-13. 2705275, 19574486.
25. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V. An Immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 2011, 144(2-3):170-179.
26. Misdorp W, Else RW, Hellmen E, Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat 1999, Washington, D.C.: Armed Forces Institute of Pathology.
27. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol 1998, 119(3):263-275. 10.1016/S0021-9975(98)80049-2, 9807728.
28. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5(5):1183-1189. 10.1158/1535-7163.MCT-05-0400, 16731750.
29. Ordas J, Millan Y, Dios R, Reymundo C, Mulas JM D. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179. 10.1186/1471-2407-7-179, 2045669, 17880730.
30. Takauji SR, Watanabe M, Uyama R, Nakagawa T, Miyajima N, Mochizuki M, Nishimura R, Sugano S, Sasaki N. Expression and subcellular localization of E-cadherin, alpha-catenin, and beta-catenin in 8 feline mammary tumor cell lines. J Vet Med Sci 2007, 69(8):831-834. 10.1292/jvms.69.831, 17827890.
31. Minke JM, Weijer K, Misdorp W. Allotransplantation of K248 feline mammary carcinoma cell line in cats, A model for monoclonal antibody guided detection and therapy of human breast cancer. Lab Invest 1991, 65(4):421-432.
32. Muleya JS, Nakaichi M, Sugahara J, Taura Y, Murata T, Nakama S. Establishment and characterization of a new cell line derived from feline mammary tumor. J Vet Med Sci 1998, 60(8):931-935. 10.1292/jvms.60.931, 9764406.
33. Muleya JS, Nakaichi M, Taura Y, Yamaguchi R, Nakama S. In-vitro anti-proliferative effects of some anti-tumour drugs on feline mammary tumour cell lines. Res Vet Sci 1999, 66(3):169-174. 10.1053/rvsc.1998.0218, 10333454.
34. Uyama R, Hong SH, Nakagawa T, Yazawa M, Kadosawa T, Mochizuki M, Tsujimoto H, Nishimura R, Sasaki N. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci 2005, 67(12):1273-1276. 10.1292/jvms.67.1273, 16397390.
35. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7(12):683-692. 10.1038/nrclinonc.2010.154, 20877296.
36. Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1):20-26. 10.1016/j.breast.2011.09.006, 21983489.
37. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 2012, 103(9):1665-1671. 10.1111/j.1349-7006.2012.02359.x, 22703543.
38. Hughes K, Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J 2012, 194:1. 10.1016/j.tvjl.2012.08.028, 23026715.
39. Chen Y-T, Tan KAL, Pang LY, Argyle DJ. The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res 2012, 8:73. 10.1186/1746-6148-8-73, 3515332, 22647622.
40. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, Oyama T. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 2012,
41. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008, 110(3):477-483. 10.1007/s10549-007-9746-x, 17805960.
42. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418(6901):934. 10.1038/418934a, 12198537.
43. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003, 63(14):3955-3957.
44. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012, 14(2):129-138. 10.1007/s11912-012-0227-y, 22350330.